AUREOMYCIN IN TREATMENT OF EXPERIMENTAL AND HUMAN TULAREMIA
- 26 March 1949
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 139 (13) , 830-832
- https://doi.org/10.1001/jama.1949.02900300016005
Abstract
The new antibiotic, aureomycin, first described by Duggar,1has been shown to exert specific effect when administered to patients suffering with diseases caused by gram-negative2and certain gram-positive organisms.2bDetailed reports of its usefulness in rickettsial infections have now been recorded, and aureomycin perhaps exerts its greatest influence in this group of diseases.3Favorable results from its employment in lymphogranuloma inguinale have been published.4No toxic effects other than nausea and occasional diarrhea attributable to the drug have been observed in our experience or in the patients who have been treated with this agent and reported in the medical literature. We have been interested in the chemotherapy of tularemia since 1947, when para-aminobenzoic acid (PABA) was observed by us to exert slight benefit in mice experimentally infected with Bacterium tularense. This effect, however, did not in any way approach that achieved with streptomycin, but inKeywords
This publication has 0 references indexed in Scilit: